FEB 09, 2017 4:27 PM PST

Key Genetic Defect in Brain Tumor Cells

WRITTEN BY: Jennifer Ellis

Some malignant tumors found in brain cancer patients or in some types of leukemia have specific mutations in the IDH1 or IDH2 genes. Mutations within these genes cause an overproduction of 2-hydroxyglutarate (2HG), which is a known metabolite that promotes carcinogenesis. The overproduction of this metabolite causes impaired homologous recombination in the tumor cells and induces a sensitivity to PARP inhibitor-type cancer drugs. A mutant cell’s sensitivity to these specific cancer drugs stems from an enhancement in the cell’s susceptibility to DNA-damaging agents.  

Cancer cells in the brain

PARP inhibitors disrupt the enzyme poly ADP ribose polymerase (PARP). The drugs were created to treat different forms of cancer. Certain types of cancer tend to be more dependent on the PARP enzyme in maintaining their DNA integrity and initiating programmed cell death than healthy cells. This makes PARP an appealing and specific target for cancer therapies.

Traditional therapies for IDH1/2 mutations in cancer cells block the overproduction of 2HG with the intention of decreasing tumor growth by stopping tumor progression. However, new data suggest that since 2HG also negatively affects homologous recombination, that the target should be inhibiting DNA repair mechanisms that can then kill the tumor cells instead of trying to regulate 2HG. By inhibiting DNA repair mechanisms and exposing cells to drugs that harm DNA, the cells cannot survive.

A research group from Yale University, led by senior authors Ranjit Bindra and Peter Glazer, created different cell lines with IDH1 and IDH2 mutations to test various cancer drugs for sensitivity to blocked DNA repair. Their findings highlighted the ovarian cancer drug, olaparib, which caused a 50-fold increase in brain tumor cell death.

“Our work at Yale has practice-changing implications, as our data suggest an entirely new group of tumors can be targeted effectively with DNA repair inhibitors, and that possibly these patients currently are not being treated with the most optimal approaches,” said senior author Dr. Ranjit Bindra, assistant professor of therapeutic radiology and of experimental pathology.

Co-senior author Dr. Peter Glazer, professor of therapeutic radiology and of genetics, added, “Our work raises serious caution regarding current therapeutic strategies that are aimed at blocking mutant IDH1 and IDH2 protein function, as we believe the DNA repair defect should be exploited rather than blocked.”

The results from the cell line experiments are robust enough to begin planning clinical trials around the approach. The clinical trials will further test the ability for DNA repair inhibitors to successfully halt the growth and potentially even cause the death of brain tumor cells that contain IDH1 and IDH2 mutations. With the sensitivity observed in mutant cells treated with olaparib, the team is confident that they will see a similar effect in people.

Sources: Yale News, Science Translational Medicine

About the Author
  • I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
MAY 05, 2020
Cell & Molecular Biology
Preprint Suggests Sars-CoV-2 Mutation Makes it More Transmissable
MAY 05, 2020
Preprint Suggests Sars-CoV-2 Mutation Makes it More Transmissable
Samples obtained from patients from all over the world have been used to sequence the genomes of the viral strains infec ...
MAY 31, 2020
Genetics & Genomics
Regulating Gene Expression with Electricity
MAY 31, 2020
Regulating Gene Expression with Electricity
Scientists have created many different implantable devices and medicines that are as simple as pacemakers or as complex ...
JUN 20, 2020
Cancer
A New MicroRNA Linked to the Suppression of Ovarian Cancer
JUN 20, 2020
A New MicroRNA Linked to the Suppression of Ovarian Cancer
One of the things a cancer patient can hear from their doctor is “recurrence.” Modern cancer therapies are a ...
JUN 22, 2020
Microbiology
A Human Gut Microbe Can Help Maintain Healthy Cholesterol Levels
JUN 22, 2020
A Human Gut Microbe Can Help Maintain Healthy Cholesterol Levels
The world is full of microorganisms, and our bodies are one of the many places they have colonized. These gut microbes c ...
JUN 29, 2020
Genetics & Genomics
Why Two Similar Bacterial Toxins Cause Different Illnesses
JUN 29, 2020
Why Two Similar Bacterial Toxins Cause Different Illnesses
The microbial pathogens of the world have shown us how powerful they can be, most recently proven by the current pandemi ...
JUL 28, 2020
Immunology
Neonatal Origins of Chronic Inflammatory Disease
JUL 28, 2020
Neonatal Origins of Chronic Inflammatory Disease
From birth, our genes write the story of our lives. For many people who develop chronic immune and inflammatory diseases ...
Loading Comments...